<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094168</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRA CT 2017-005144-14</org_study_id>
    <nct_id>NCT04094168</nct_id>
  </id_info>
  <brief_title>Clinical Impact of Del Nido Cardioplegia in Adult Cardiac Surgery</brief_title>
  <official_title>Clinical Outcomes of Del Nido Cardioplegia in Adult Cardiac Surgery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JESSICA GARCIA SUAREZ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puerta de Hierro University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardioplegia solutions have been used for myocardial protection in cardiac surgery for
      decades. Different cardioplegic strategies have been evaluated.

      Del Nido cardioplegia was initially used in pediatric patients and has been expanding into
      adult cardiac centers over the last decade. It can be used as a single dose and it is a
      reasonable tool do decrease cardioplegic interventions. Recent meta-analysis based on 9
      retrospective studies has shown that &quot;clinical outcomes of Del Nido cardioplegia are
      noninferior to the outcomes of conventional cardioplegia in adult cardiac surgery&quot;.

      To assess the potencial benefits of Del Nido cardioplegia we performed this clinical trial to
      evaluate superiority of Del Nido cardioplegia compared to cold blood cardioplegia in terms of
      myocardial protection and clinical-related outcomes. 474 participants will be randomized
      either into Del Nido cardioplegia protocol or into the cold blood cardioplegia protocol.
      Perioperative outcomes will be presented.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is performed at Puerta de Hierro Hospital in Spain. The protocol has been
      approved by institutional ethical committee and Spanish Agency of medicines and medical
      devices (AEMPS).

      The aim of the study is to evaluate superiority of Del Nido cardioplegia solution compared to
      cold blood cardioplegia solution in terms of myocardial protection and clinical-related
      outcomes.

      According to results in recent meta-analysis, the author estimated a total sample size of 474
      participants to give 80 % of power at the 5% significant level.

      Participants aged 18 years or older undergoing elective cardiac surgery are randomized 1:1 to
      receive Del Nido cardioplegia solution (study group) and cold blood cardioplegia solution
      (control group).

      Primary outcome will be assessed by biochemical variables of myocardial injury (troponin T
      level at inmediate post-op, 3-12 hours, 12-24 hours, 24-48 hours post-op); and clinical
      variables: &quot;Presence of acute myocardial infarction within 72 hours after surgery&quot;,
      &quot;Prolonged low cardiac output&quot;, &quot;Prolonged postoperative vasoplegia&quot; within 48 hours after
      surgery and/or &quot;Ventricular tachyarrythmias&quot; within 24 hours after surgery.

      Secondary outcomes include intraoperative variables of myocardial protection (incidence of
      ventricular fibrillation, inotropic and vasopressor support at the end of surgical
      intervention, cardiopulmonary bypass time, aortic cross-clamp time) and postoperative
      clinical outcomes variables (mechanical ventilation time, incidence of delirium, stroke,
      acute renal failure, atrial fibrillation, length of stay in intensive care unit, length of
      stay in hospital and In-hospital mortality).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood troponin levels.</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>Biochemical variables of myocardial injury: Blood troponin levels measured at admission in intensive care unit, 12, 24, 48 hours post-op.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute cardiovascular event.</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Composite outcome of clinical events &quot;Prolonged low cardiac output&quot;, &quot;Prolonged postoperative vasoplegia&quot;, &quot;Ventricular tachyarrythmias&quot; and/or &quot;Acute myocardial infarction&quot;.
Prolonged low cardiac output. Inotropic pharmacologic support more than 48 hours in intensive care unit and/or mechanical circulatory support.
Prolonged postoperative vasoplegia. Vasopressor support more than 48 hours in intensive care unit.
Ventricular tachyarrythmias. Ventricular fibrillation and hemodynamically unstable ventricular tachycardia within 24 hours after surgery.
Acute myocardial infarction within 72 hours after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventricular fibrillation after aortic cross-clamp removal.</measure>
    <time_frame>Intraoperative.</time_frame>
    <description>Incidence of ventricular fibrillation after aortic cross-clamp removal (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defibrillation requirement.</measure>
    <time_frame>Intraoperative.</time_frame>
    <description>Defibrillation requirement after aortic cross-clamp removal (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioplegia delivery.</measure>
    <time_frame>Intraoperative.</time_frame>
    <description>Cardioplegia delivery (antegrade, retrograde, both).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary bypass time (CBP).</measure>
    <time_frame>Intraoperative.</time_frame>
    <description>Duration of cardiopulmonary bypass (CBP) (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic cross-clamp time</measure>
    <time_frame>Intraoperative.</time_frame>
    <description>Duration of aortic cross-clamp time (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to cardiopulmonary bypass.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Failure to separate from cardiopulmonary bypass (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative packed red blood cells transfusion.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative packed red blood cells transfusion (U).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative maximal blood glucose concentration.</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative maximal blood glucose concentration (mg/dl).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative atrial fibrillation.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>New-onset atrial fibrillation or hemodynamically unstable atrial fibrillation that requires treatment (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation.</measure>
    <time_frame>Up to 24 hours.</time_frame>
    <description>Reoperation within 24 hours after surgery (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotropic or vasopressor support in intensive care unit.</measure>
    <time_frame>At admission in intensive care unit, 24, 48 hours.</time_frame>
    <description>Inotropic or vasopressor support in intensive care unit (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of inotropic support after cardiopulmonary bypass.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>Duration of inotropic support after cardiopulmonary bypass (hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>Mechanical ventilation time (min).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute renal failure.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>Incidence of renal failure (Requirement for postoperative renal replacement therapy) (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>Incidence of ischemic stroke (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium.</measure>
    <time_frame>Up to 2 weeks.</time_frame>
    <description>Incidence of delirium (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative packed red blood cells transfusion.</measure>
    <time_frame>Up to 1 week.</time_frame>
    <description>Postoperative packed red blood cells transfusion (U)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>through study completion, an average 1 month.</time_frame>
    <description>Length of stay in intensive care unit (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>through study completion, an average 6 months.</time_frame>
    <description>Length of stay in hospital (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative ventricular ejection fraction change.</measure>
    <time_frame>through study completion, an average 6 months.</time_frame>
    <description>Postoperative ventricular ejection fraction (LVEF) change (Y/N).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality.</measure>
    <time_frame>through study completion, an average 6 months.</time_frame>
    <description>Mortality (Y/N).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">474</enrollment>
  <condition>Heart; Surgery, Heart, Functional Disturbance as Result</condition>
  <arm_group>
    <arm_group_label>Del Nido Cardioplegia solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 liter of Del Nido cardioplegia after aortic cross-clamp will be given. Additional dose will be applied if aortic cross-clamp exceeds 90 minutes or whenever cardiac activity is observed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cold blood Cardioplegia solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administering of cardioplegia using current standard of care blood-based cardioplegia protocol. An induction dose of whole blood cardioplegia will be given at a temperature of 4-8 degrees, with subsequent doses of cardioplegia every 20 minutes or whenever cardiac activity is observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEL NIDO CARDIOPLEGIA</intervention_name>
    <description>Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).
Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.</description>
    <arm_group_label>Del Nido Cardioplegia solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COLD BLOOD BASED CARDIOPLEGIA</intervention_name>
    <description>Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.</description>
    <arm_group_label>Cold blood Cardioplegia solution</arm_group_label>
    <other_name>CARDIBRAUN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 years or older undergoing adult cardiac surgery.

          -  Elective surgical procedures requiring cardiopulmonary bypass and myocardial arrest.

        Exclusion Criteria:

          -  Emergency surgery.

          -  Patients on preoperative inotropic support and/or mechanical circulatory support.

          -  Patient who refuse to participate in the study.

          -  Lidocaine allergy.

          -  Port access mitral valve surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica García Suárez</last_name>
    <phone>+34660164436</phone>
    <email>jessicag.suarez@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alberto Forteza Gil</last_name>
    <phone>+34636275497</phone>
    <email>apforteza@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Puerta de Hierro Hospital</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica García Suárez</last_name>
      <phone>+34660164436</phone>
      <email>jessicag.suarez@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alberto Forteza Gil, MD</last_name>
      <phone>+34636275497</phone>
      <email>apforteza@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica García Suárez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Buckberg GD, Athanasuleas CL. Cardioplegia: solutions or strategies? Eur J Cardiothorac Surg. 2016 Nov;50(5):787-791. Epub 2016 Jul 1.</citation>
    <PMID>27369117</PMID>
  </reference>
  <reference>
    <citation>Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM, Fitzgerald D. The use of del Nido cardioplegia in adult cardiac surgery: A prospective randomized trial. J Thorac Cardiovasc Surg. 2018 Mar;155(3):1011-1018. doi: 10.1016/j.jtcvs.2017.09.146. Epub 2017 Nov 13.</citation>
    <PMID>29246552</PMID>
  </reference>
  <reference>
    <citation>Li Y, Lin H, Zhao Y, Li Z, Liu D, Wu X, Ji B, Gao B. Del Nido Cardioplegia for Myocardial Protection in Adult Cardiac Surgery: A Systematic Review and Meta-Analysis. ASAIO J. 2018 May/Jun;64(3):360-367. doi: 10.1097/MAT.0000000000000652.</citation>
    <PMID>28863040</PMID>
  </reference>
  <reference>
    <citation>Lazar HL. del Nido cardioplegia: Passing fad or here to stay? J Thorac Cardiovasc Surg. 2018 Mar;155(3):1009-1010. doi: 10.1016/j.jtcvs.2017.09.126. Epub 2017 Oct 10.</citation>
    <PMID>29110949</PMID>
  </reference>
  <reference>
    <citation>Tam DY, Fremes SE. Del Nido cardioplegia: A one stop shot for adult cardiac surgery? J Thorac Cardiovasc Surg. 2018 Mar;155(3):1019-1020. doi: 10.1016/j.jtcvs.2017.10.066. Epub 2017 Oct 31.</citation>
    <PMID>29198802</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Puerta de Hierro University Hospital</investigator_affiliation>
    <investigator_full_name>JESSICA GARCIA SUAREZ</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Del Nido Cardioplegia</keyword>
  <keyword>Cardioplegia</keyword>
  <keyword>Adult Cardiac Surgery</keyword>
  <keyword>Myocardial protection</keyword>
  <keyword>Heart surgery</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>6 months after publication.</ipd_time_frame>
    <ipd_access_criteria>Access by mail to principal investigator: Jessica.suarez@gmail.com Access by mail to sponsor: apforteza@yahoo.es</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

